SciSparc Ltd. Ordinary Shares (SPRC)
SciSparc Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) disorders. The company specializes in leveraging proprietary formulations of cannabinoids and other compounds to address conditions such as schizophrenia, autism spectrum disorder, and other neurological and psychiatric conditions. SciSparc aims to advance innovative therapies through research and clinical trials to improve patient outcomes in CNS health.
Company News
SciSparc Ltd. has entered into an agreement to acquire a controlling interest in Miza III Ventures Inc., transferring its advanced clinical stage pharmaceutical portfolio and equity stake in SciSparc Nutraceuticals Inc. The transaction values the target assets at approximately $11.6 million and is expected to close around October 22, 2025.
Over 50 companies are advancing cannabinoid drug research, exploring potential treatments for mental health disorders, neurodegenerative diseases, and chronic inflammation, with promising clinical trials targeting conditions like Alzheimer's, pain management, and epilepsy.
Use these tips to handle short term penny stocks price movements The post Dealing With Penny Stocks’ Short Term Price Movements appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.